Albiges, Laurence

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 5,671

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 908

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Motzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., Mu, X. J., Ching, K. A., Uemura, M., Pal, S. K., et al. (2020) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 518

Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

Derosa, L., Routy, B., Fidelle, M., Iebba, V., Alla, L., Pasolli, E., Segata, N., Desnoyer, A., Pietrantonio, F., Ferrere, G., et al. (2020) · European Urology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 398

Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 396

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

Danlos, F.-X., Voisin, A.-L., Dyevre, V., Michot, J.-M., Routier, E., Taillade, L., Champiat, S., Aspeslagh, S., Haroche, J., Albiges, L., et al. (2018) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 300

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Choueiri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Drake, C. G., Kluger, H., Stadler, W. M., Perez-Gracia, J. L., McNeel, D. G., Curti, B., et al. (2016) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 295

A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers

Fidelle, M., Rauber, C., Alves Costa Silva, C., Tian, A.-L., Lahmar, I., de La Varende, A.-L. M., Zhao, L., Thelemaque, C., Lebhar, I., Messaoudene, M., et al. (2023) · Science

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 243

Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 198

Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel–Lindau gene mutation status

Messai, Y., Gad, S., Noman, M. Z., Le Teuff, G., Couve, S., Janji, B., Kammerer, S. F., Rioux-Leclerc, N., Hasmim, M., Ferlicot, S., et al. (2016) · European Urology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 168

ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy

Messai, Y., Noman, M. Z., Hasmim, M., Janji, B., Tittarelli, A., Boutet, M., Baud, V., Viry, E., Billot, K., Nanbakhsh, A., et al. (2014) · Cancer Research

Immune Cell Function and InteractionAutophagy in Disease and Therapy

Cited by 119

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

Rini, B. I., Moslehi, J. J., Bonaca, M., Schmidinger, M., Albiges, L., Choueiri, T. K., Motzer, R. J., Atkins, M. B., Haanen, J., Mariani, M., et al. (2022) · Journal of Clinical Oncology

Renal cell carcinoma treatmentChemotherapy-induced cardiotoxicity and mitigation

Cited by 77

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

Grimm, M.-O., Esteban, E., Barthélémy, P., Schmidinger, M., Busch, J., Valderrama, B. P., Charnley, N., Schmitz, M., Schumacher, U., Leucht, K., et al. (2023) · The Lancet Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 37

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

Albiges, L., Bourlon, M. T., Chacón, M., Cutuli, H. J., Chuken, Y. A. L., Żurawski, B., Mota, J. M., Magri, I., Burotto, M., Luz, M., et al. (2025) · Annals of Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 31

Surrogate markers of intestinal dysfunction associated with survival in advanced cancers

Birebent, R., Drubay, D., Alves Costa Silva, C., Marmorino, F., Vitali, G., Piccinno, G., Hurtado, Y., Bonato, A., Belluomini, L., Messaoudene, M., et al. (2025) · OncoImmunology

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 21

Feasibility of a video-based cognitive behavioral therapy for insomnia in French adult cancer outpatients: results from the Sleep-4-All-1 study

Boinon, D., Charles, C., Fasse, L., Journiac, J., Pallubicki, G., Lamore, K., Ninot, G., Guerdoux-Ninot, E., Gouy, S., Albiges, L., et al. (2021) · Supportive Care in Cancer

Sleep and related disordersDigital Mental Health Interventions

Cited by 12

Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a Phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma

Pal, S. K., Tannir, N. M., Grell, P., Gao, X., Kotecha, R. R., Picus, J., De Braud, F. G., Takahashi, S., Wong, A., Suárez, C., et al. (2024) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 9

Impact of microbiota specific circulating memory T cells in response to immunotherapy.

Gattazzo, F., Birebent, R., Lebhar, I., Xiberras, M., Marques, M., Reni, A., Flament, C., Bonato, A., Belluomini, L., Chanfreau-Paris, H., et al. (2024) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 4

Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.

Saliby, R. M., Machaalani, M., Zhong, C., Alves Costa Silva, C., Labaki, C., Saad, E., Steiner, C., Yekeduz, E., Eid, M., Daoud Khatoun, W., et al. (2025) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 2